Robotic Bronchoscopy Boosts Early Lung Cancer Detection by 85%

Lung cancer remains the leading cause of cancer deaths, yet early detection significantly improves survival rates. A recent five-year study by the Mayo Clinic shows that advanced robotic bronchoscopy can now identify malignant lung growths with 85% sensitivity. This technology could transform how suspicious nodules are diagnosed and treated. Each year, around 1.6 million suspicious lung nodules are found in US screening programmes. Most of these lesions turn out to be benign, but distinguishing them from malignant ones is critical. The Mayo Clinic's study revealed that over half (56%) of the sampled lesions were cancerous, while 21% were confirmed benign and 23% remained inconclusive under strict diagnostic standards.

The research focused on shape-sensing robotic-assisted bronchoscopy, a method that allows precise navigation through complex airway pathways. Clinicians can now sample multiple nodules across both lungs with greater accuracy than before. When combined with endobronchial ultrasound (EBUS), the system also enables real-time staging by biopsying nearby lymph nodes. Safety was another key finding, with complications occurring in just 2.8% of procedures. The overall diagnostic accuracy reached nearly 77% when applying updated national criteria. Beyond diagnosis, robotic platforms are being paired with treatments like pulsed electric field ablation (PEF) for minimally invasive therapy. Despite its promise, the Mayo Clinic's approach—merging robotic bronchoscopy with mobile cone-beam CT—remains specialised. As of April 2026, widespread adoption is still limited, with no public record of how many centres have fully integrated the technology into routine care.

The study confirms that early detection through robotic bronchoscopy can drastically improve lung cancer outcomes. With a five-year survival rate of 67% for localised cases—compared to just 12% for metastatic disease—the technology offers a clearer path to timely intervention. Its high sensitivity and low complication rate suggest a potential shift in how lung nodules are managed in the future.